Aurora Cannabis (TSE:ACB) Stock Rating Upgraded by Atb Cap Markets

Aurora Cannabis (TSE:ACB) was upgraded by research analysts at Atb Cap Markets from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

A number of other brokerages have also recently commented on ACB. TD Securities upgraded Aurora Cannabis to a “strong-buy” rating in a research note on Thursday, December 12th. ATB Capital cut their price target on Aurora Cannabis from C$11.00 to C$8.50 in a research note on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of C$5.85.

Aurora Cannabis Stock Performance

Aurora Cannabis stock opened at C$8.63 on Wednesday. The company has a quick ratio of 2.48, a current ratio of 3.76 and a debt-to-equity ratio of 16.95. The stock has a market cap of C$471.72 million, a PE ratio of -13.70 and a beta of 2.71. Aurora Cannabis has a 12-month low of C$3.84 and a 12-month high of C$12.85. The business’s 50-day moving average price is C$6.08 and its two-hundred day moving average price is C$7.18.

Aurora Cannabis (TSE:ACB) last released its quarterly earnings data on Wednesday, November 6th. The company reported C$0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of C($0.30) by C$0.35. Aurora Cannabis had a negative net margin of 11.53% and a negative return on equity of 6.13%. During the same quarter in the previous year, the business posted ($0.70) earnings per share. As a group, analysts expect that Aurora Cannabis will post -0.22 earnings per share for the current fiscal year.

About Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.